Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-5684 in Male Participants With Severe Renal Impairment and With End-stage Renal Disease

Next Previous
Search
Trial Profile

An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-5684 in Male Participants With Severe Renal Impairment and With End-stage Renal Disease

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Opevesostat (Primary) ; Fludrocortisone; Prednisone
  • Indications Prostate cancer; Renal failure
  • Focus Pharmacokinetics
  • Sponsors Merck Sharp & Dohme

Most Recent Events

  • 17 Apr 2025 Planned End Date changed from 19 Aug 2025 to 22 Aug 2025.
  • 17 Apr 2025 Planned primary completion date changed from 12 Aug 2025 to 15 Aug 2025.
  • 17 Apr 2025 Planned initiation date (estimated date of first participant enrollement) changed from 25 Mar 2025 to 9 Apr 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top